Trials / Completed
CompletedNCT01046318
A Study of OPC-262 in Patients With Type 2 Diabetes
A Long-term Study of OPC-262 in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-262 | OPC-262 5 mg will be orally administered once daily fro 52 weeks. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-01-11
- Last updated
- 2014-01-08
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01046318. Inclusion in this directory is not an endorsement.